Aprepitant Patent Expiration

1. Aponvie patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9974742 HERON THERAPS INC Emulsion formulations of an NK-1 receptor antagonist and uses thereof
Sep, 2035

(11 years from now)

US11173118 HERON THERAPS INC Emulsion formulations of an NK-1 receptor antagonist and uses thereof
Sep, 2035

(11 years from now)

US10953018 HERON THERAPS INC Emulsion formulations of aprepitant
Sep, 2035

(11 years from now)

US10624850 HERON THERAPS INC Emulsion formulations of an NK-1 receptor antagonist and uses thereof
Sep, 2035

(11 years from now)

US9974794 HERON THERAPS INC Emulsion formulations of aprepitant
Sep, 2035

(11 years from now)

US9808465 HERON THERAPS INC Emulsion formulations of aprepitant
Sep, 2035

(11 years from now)

US9974793 HERON THERAPS INC Emulsion formulations of aprepitant
Sep, 2035

(11 years from now)

US11744800 HERON THERAPS INC Methods of use of emulsion formulations of an NK-1 receptor antagonist
Sep, 2035

(11 years from now)

US11878074 HERON THERAPS INC Methods of use of emulsion formulations of an NK-1 receptor antagonist
Sep, 2035

(11 years from now)

US10500208 HERON THERAPS INC Emulsion formulations of aprepitant
Sep, 2035

(11 years from now)

US9561229 HERON THERAPS INC Emulsion formulations of aprepitant
Sep, 2035

(11 years from now)




Market Authorisation Date: 16 September, 2022

Treatment: A method of administering aprepitant for prevention of post-operative nausea and vomiting; A method for preventing of post-operative nausea and vomiting; A method for preventing post-operative nausea ...

Dosage: EMULSION

More Information on Dosage

APONVIE family patents

Family Patents

2. Cinvanti patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11173118 HERON THERAPS INC Emulsion formulations of an NK-1 receptor antagonist and uses thereof
Sep, 2035

(11 years from now)

US10500208 HERON THERAPS INC Emulsion formulations of aprepitant
Sep, 2035

(11 years from now)

US11744800 HERON THERAPS INC Methods of use of emulsion formulations of an NK-1 receptor antagonist
Sep, 2035

(11 years from now)

US10953018 HERON THERAPS INC Emulsion formulations of aprepitant
Sep, 2035

(11 years from now)

US9808465 HERON THERAPS INC Emulsion formulations of aprepitant
Sep, 2035

(11 years from now)

US9974794 HERON THERAPS INC Emulsion formulations of aprepitant
Sep, 2035

(11 years from now)

US9561229 HERON THERAPS INC Emulsion formulations of aprepitant
Sep, 2035

(11 years from now)

US10624850 HERON THERAPS INC Emulsion formulations of an NK-1 receptor antagonist and uses thereof
Sep, 2035

(11 years from now)

US9974793 HERON THERAPS INC Emulsion formulations of aprepitant
Sep, 2035

(11 years from now)

US9974742 HERON THERAPS INC Emulsion formulations of an NK-1 receptor antagonist and uses thereof
Sep, 2035

(11 years from now)




Market Authorisation Date: 09 November, 2017

Treatment: Treatment of nausea and vomiting, including the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly or moderately emetogenic cancer chemotherapy

Dosage: EMULSION

How can I launch a generic of CINVANTI before it's drug patent expiration?
More Information on Dosage

CINVANTI family patents

Family Patents

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

3. Emend patent expiration

EMEND's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7214692 MERCK Medical use for tachykinin antagonists
Sep, 2012

(11 years ago)

US5538982 MERCK Medical use for tachykinin antagonists
Jul, 2013

(10 years ago)

US5719147 MERCK Morpholine and thiomorpholine tachykinin receptor antagonists
Apr, 2015

(9 years ago)

US6096742 MERCK Polymorphic form of a tachykinin receptor antagonist
Jul, 2018

(6 years ago)

US8258132 MERCK Pharmaceutical composition of a tachykinin receptor antagonist
Sep, 2027

(3 years from now)




Drug Exclusivity Drug Exclusivity Expiration
M(M-82) Mar 19, 2013
New Patient Population(NPP) Aug 28, 2018

Market Authorisation Date: 30 June, 2006

Treatment: Treatment or prevention of emesis; For the prevention of nausea and vomiting associated with chemotherapy

Dosage: CAPSULE

How can I launch a generic of EMEND before it's drug patent expiration?
More Information on Dosage

EMEND family patents

Family Patents

4. Emend patent expiration

EMEND's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6096742 MSD MERCK CO Polymorphic form of a tachykinin receptor antagonist
Jul, 2018

(6 years ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8258132 MSD MERCK CO Pharmaceutical composition of a tachykinin receptor antagonist
Sep, 2027

(3 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Patient Population(NPP) Aug 28, 2018

Market Authorisation Date: 17 December, 2015

Treatment: Prevention of nausea and vomiting associated with chemotherapy (cinv)

Dosage: FOR SUSPENSION

How can I launch a generic of EMEND before it's drug patent expiration?
More Information on Dosage

EMEND family patents

Family Patents